Literature DB >> 25619540

Is type 2 diabetes mellitus a predisposal cause for developing hepatocellular carcinoma?

Biswajit Mukherjee, Sanchari Bhattacharya, Samrat Chakraborty, Bhabani Sankar Satapathy, Niladri Shekhar Dey, Tapan Kumar Shaw1.   

Abstract

Hepatic cancer stands as one of the frontier causes of cancer related mortality worldwide. Among the several risk factors already established, type 2 diabetes is now considered as one of the important risks in progression of liver cancer. Studies have shown that likelihood of occurrence of liver cancer is many folds higher in patients diagnosed with type II diabetes compared to patients without diabetes. Liver plays an important role in metabolism of glucose in our body, so may be type II diabetes as it is an important epiphenomenon of hepatic diseases such as liver cirrhosis, liver failure, fatty liver, chronic hepatitis and hepatocellular carcinoma. Some reports suggested that extensive change in enzyme structures in molecular level in diabetic patients may lead to liver function damage and hence accelerate hepatic cancer. Other strong links between these two diseases are "non alcoholic fatty liver diseases" and "nonalcoholic steatohepatitis" which are metabolic disorders caused by type II diabetes and eventually develops hepatocellular carcinoma. However, it still remains unanswered whether prevention of diabetes would effectively lower the chances of developing liver cancer or eliminating diabetes from the population would effectively reduce the liver cancer incidence. In this review, we will primarily focus on the molecular link between type2 diabetes and hepatic cancer and investigate underlying mechanism to establish type II diabetes as predisposed cause of hepatic cancer.

Entities:  

Mesh:

Year:  2015        PMID: 25619540     DOI: 10.2174/1573399811666150115110747

Source DB:  PubMed          Journal:  Curr Diabetes Rev        ISSN: 1573-3998


  4 in total

1.  Antidiabetic treatment improves prognosis after radical resection in hepatocellular carcinoma patients with diabetes mellitus: a retrospective cohort study from 2000 to 2013.

Authors:  Jing-Zhu Cao; Zhen-Guang Wang; Jian Yu; Yuan-Ping Tao; Yuan Yang; Hui Liu; Wei-Ping Zhou; Jin Lu; Qin Huang
Journal:  J Gastrointest Oncol       Date:  2022-06

2.  Identifying key genes and screening therapeutic agents associated with diabetes mellitus and HCV-related hepatocellular carcinoma by bioinformatics analysis.

Authors:  Muhammad Sufyan; Usman Ali Ashfaq; Sajjad Ahmad; Fatima Noor; Muhammad Hamzah Saleem; Muhammad Farhan Aslam; Hamed A El-Serehy; Sidra Aslam
Journal:  Saudi J Biol Sci       Date:  2021-07-30       Impact factor: 4.219

Review 3.  O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy.

Authors:  Qingsong Lu; Xiaozhen Zhang; Tingbo Liang; Xueli Bai
Journal:  Mol Med       Date:  2022-09-14       Impact factor: 6.376

4.  PFKFB3, a key glucose metabolic enzyme regulated by pathogen recognition receptor TLR4 in liver cells.

Authors:  Yan Lu; Lei Zhang; Ran Zhu; Huijuan Zhou; Huaying Fan; Qiang Wang
Journal:  Ther Adv Endocrinol Metab       Date:  2020-05-27       Impact factor: 4.435

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.